Advertisement
UK markets open in 1 hour 39 minutes

  • NIKKEI 225

    37,123.56
    -956.14 (-2.51%)
     

  • HANG SENG

    16,228.39
    -157.48 (-0.96%)
     

  • CRUDE OIL

    84.44
    +1.71 (+2.07%)
     

  • GOLD FUTURES

    2,397.70
    -0.30 (-0.01%)
     

  • DOW

    37,775.38
    +22.07 (+0.06%)
     

  • Bitcoin GBP

    49,873.67
    +207.30 (+0.42%)
     

  • CMC Crypto 200

    1,287.31
    +401.77 (+44.17%)
     

  • NASDAQ Composite

    15,601.50
    -81.87 (-0.52%)
     

  • UK FTSE All Share

    4,290.02
    +17.00 (+0.40%)
     
Money:

Best mortgage deals of the week

As possibility of multiple interest rate cuts dwindle here's what banks and building societies are offering

Veracyte to Participate in Upcoming Investor Conferences

Business Wire
·2-min read

SOUTH SAN FRANCISCO, Calif., May 23, 2023--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and Rebecca Chambers, chief financial officer, will participate in two upcoming investor conferences:

  • William Blair 43rd Annual Growth Stock Conference – Chicago, IL
    Presentation on June 6th at 9:40 a.m. Eastern Time

  • Goldman Sachs 44th Annual Global Healthcare Conference – Dana Point, CA
    Fireside Chat on June 13th at 6:20 p.m. Eastern Time

Live audio webcasts of the company’s presentations will be available by visiting Veracyte’s website at http://investor.veracyte.com/events-presentations. A replay of the webcasts will be available for 90 days following the conclusion of the live presentation broadcast.

ADVERTISEMENT

About Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our high-performing tests enable clinicians to make more confident diagnostic, prognostic, and treatment decisions for some of the most challenging diseases such as thyroid, prostate, breast, bladder and lung cancers, as well as interstitial lung diseases. We help patients avoid unnecessary procedures and speed time to diagnosis and appropriate treatment. In addition to making our tests available in the U.S. through our central laboratories, we also aim to deliver our tests to patients worldwide through a distributed model to laboratories that can perform them locally. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).

View source version on businesswire.com: https://www.businesswire.com/news/home/20230523006058/en/

Contacts

Investors:
Shayla Gorman
Director, Investor Relations
investors@veracyte.com
619-393-1545

Media:
Tracy Morris
Vice President of Global Corporate Communications
tracy.morris@veracyte.com
650-380-4413